These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15485606)

  • 21. Clinical trial assessment of lipid-acting drugs in diabetic patients.
    Steiner G
    Am J Cardiol; 1998 Apr; 81(8A):58F-59F. PubMed ID: 9604911
    [No Abstract]   [Full Text] [Related]  

  • 22. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
    Krentz AJ
    Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.
    Steiner G
    Diabetologia; 1996 Dec; 39(12):1655-61. PubMed ID: 9081851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid management reduces cardiovascular complications in individuals with diabetes and prediabetes.
    Gosavi A; Flaker G; Gardner D
    Prev Cardiol; 2006; 9(2):102-7; quiz 108-9. PubMed ID: 16603829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.
    Orloff DG; Blazing MA; O'Connor CM
    Am Heart J; 1999 Nov; 138(5 Pt 1):S406-12. PubMed ID: 10539805
    [No Abstract]   [Full Text] [Related]  

  • 27. Diabetes, hyperlipidemia, and coronary artery disease.
    Haffner SM
    Am J Cardiol; 1999 May; 83(9B):17F-21F. PubMed ID: 10357570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperlipidemia and fibrates with special reference to diabetes].
    Henkel E; Hanefeld M
    Herz; 2001 Dec; 26(8):523-30. PubMed ID: 11820155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of dyslipidemia in adults with diabetes.
    Haffner SM
    Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease.
    Boronat M; García-Cantón C; López-Ríos L; Quevedo V; Lorenzo DL; Batista F; Riaño M; Nóvoa FJ
    Diab Vasc Dis Res; 2014 Jan; 11(1):53-9. PubMed ID: 24254975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 32. The UKPDS: implications for the dyslipidaemic patient.
    Holman R
    Acta Diabetol; 2001; 38 Suppl 1():S9-14. PubMed ID: 11829452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic dyslipidaemia: insights for optimizing patient management.
    Vergès B
    Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of diabetic dyslipidemia.
    Garg A
    Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hyperlipidaemia in patients with non-insulin-dependent diabetes mellitus with progressive nephropathy.
    Cheng IK; Lam KS; Janus ED; Pang RW; Lauder IJ
    Contrib Nephrol; 1997; 120():79-87. PubMed ID: 9257050
    [No Abstract]   [Full Text] [Related]  

  • 36. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
    Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
    Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes.
    Mehler PS; Esler A; Estacio RO; MacKenzie TD; Hiatt WR; Schrier RW
    Am J Med; 2003 Apr; 114(5):377-82. PubMed ID: 12714127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
    Davidson MH
    Curr Atheroscler Rep; 2003 Sep; 5(5):418-22. PubMed ID: 12911853
    [No Abstract]   [Full Text] [Related]  

  • 40. Vascular disease and lipids in diabetes.
    Garber AJ
    Med Clin North Am; 1998 Jul; 82(4):931-48. PubMed ID: 9706127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.